CN114599387A - 治疗前列腺癌的免疫治疗剂 - Google Patents

治疗前列腺癌的免疫治疗剂 Download PDF

Info

Publication number
CN114599387A
CN114599387A CN202080062776.XA CN202080062776A CN114599387A CN 114599387 A CN114599387 A CN 114599387A CN 202080062776 A CN202080062776 A CN 202080062776A CN 114599387 A CN114599387 A CN 114599387A
Authority
CN
China
Prior art keywords
gnrh
seq
peptide
oligomer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080062776.XA
Other languages
English (en)
Chinese (zh)
Inventor
柯思·道格拉斯·米勒
罗伯特·博格登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heximax Treatment Co
Original Assignee
Heximax Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heximax Treatment Co filed Critical Heximax Treatment Co
Publication of CN114599387A publication Critical patent/CN114599387A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080062776.XA 2019-09-12 2020-09-10 治疗前列腺癌的免疫治疗剂 Pending CN114599387A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899553P 2019-09-12 2019-09-12
US62/899,553 2019-09-12
PCT/US2020/050194 WO2021050722A1 (en) 2019-09-12 2020-09-10 An immunotherapeutic for prostate cancer treatment

Publications (1)

Publication Number Publication Date
CN114599387A true CN114599387A (zh) 2022-06-07

Family

ID=74867215

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062776.XA Pending CN114599387A (zh) 2019-09-12 2020-09-10 治疗前列腺癌的免疫治疗剂

Country Status (10)

Country Link
US (1) US20220339238A1 (https=)
EP (2) EP4028043A4 (https=)
JP (2) JP7677953B2 (https=)
KR (1) KR20220062080A (https=)
CN (1) CN114599387A (https=)
AU (1) AU2020346818A1 (https=)
BR (1) BR112022004477A2 (https=)
CA (1) CA3152055A1 (https=)
MX (1) MX2022003100A (https=)
WO (1) WO2021050722A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916237A (zh) * 2020-05-04 2023-04-04 海克斯麦治疗公司 抗病毒病原体的疫苗
WO2024193295A1 (zh) * 2023-03-21 2024-09-26 深圳赫兹生命科学技术有限公司 去势m1病毒样颗粒亚单位疫苗及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
JP7837616B2 (ja) * 2025-07-25 2026-03-31 株式会社大都技研 遊技台

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
WO1999042472A1 (en) * 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
AU2016419048B2 (en) * 2016-08-11 2024-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
MA52591A (fr) * 2018-07-12 2021-06-02 Hexamer Therapeutics Inc Échafaudage peptidique autoassemblé
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
WO1999042472A1 (en) * 1998-02-19 1999-08-26 Igen International, Inc. Heat shock fusion-based vaccine system
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID F ZEIGLER等: "Epitope targeting with self-assembled peptide vaccines", NPJ VACCINES, vol. 4, 19 July 2019 (2019-07-19), pages 1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916237A (zh) * 2020-05-04 2023-04-04 海克斯麦治疗公司 抗病毒病原体的疫苗
WO2024193295A1 (zh) * 2023-03-21 2024-09-26 深圳赫兹生命科学技术有限公司 去势m1病毒样颗粒亚单位疫苗及其制备方法
WO2024193294A1 (zh) * 2023-03-21 2024-09-26 深圳赫兹生命科学技术有限公司 去势cmv病毒样颗粒亚单位疫苗及其制备方法

Also Published As

Publication number Publication date
BR112022004477A2 (pt) 2022-05-31
JP2025124645A (ja) 2025-08-26
WO2021050722A1 (en) 2021-03-18
CA3152055A1 (en) 2021-03-18
EP4028043A1 (en) 2022-07-20
EP4028043A4 (en) 2023-08-02
EP4183417A1 (en) 2023-05-24
US20220339238A1 (en) 2022-10-27
MX2022003100A (es) 2022-04-06
JP7677953B2 (ja) 2025-05-15
JP2022548050A (ja) 2022-11-16
KR20220062080A (ko) 2022-05-13
AU2020346818A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
KR101240547B1 (ko) Ｔ-헬퍼 및 ｂ-세포 에피토프를 포함하는 신규한 면역원성리포펩타이드
JP7677953B2 (ja) 前立腺癌処置のための免疫治療薬
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP2023524054A (ja) ベータコロナウイルスの予防と治療
CN113329762A (zh) 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
US20260061049A1 (en) Self-assembling peptide scaffold
CN113574073A (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
US20230346920A1 (en) Vaccines against viral pathogens
TW202600163A (zh) 經修飾的CMV類病毒粒子及IL-1β突變蛋白抗原之獸醫組成物
WO2016029013A2 (en) Methods for improving immunological response in vaccinated animals

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination